Origin and functional consequences of the complex I defect in Parkinson's disease
暂无分享,去创建一个
R. Swerdlow | J. Sheehan | J. Parks | J. Bennett | W. Parker | Janice K. Parks | Russell H. Swerdlow | Scott W. Miller | Robert E. Davis | Jeremy B. Tuttle | Patricia A. Trimmer | Jason P. Sheehan | James P. Bennett | W. Davis Parker | Scott W. Miller | P. Trimmer | J. Tuttle | R. Davis
[1] C. Filley,et al. Cytochrome oxidase deficiency in Alzheimer's disease , 1990, Neurology.
[2] J. Nobrega,et al. Brain Cytochrome Oxidase in Alzheimer's Disease , 1992, Journal of neurochemistry.
[3] M. King,et al. Human cells lacking mtDNA: repopulation with exogenous mitochondria by complementation. , 1989, Science.
[4] J. Langston,et al. Oxidation reactions in Parkinson's disease. Discussion , 1990 .
[5] J. Langston,et al. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.
[6] M. Quilliam,et al. On auxotrophy for pyrimidines of respiration-deficient chick embryo cells. , 1984, European journal of biochemistry.
[7] P. Löschmann,et al. Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists , 1991, Nature.
[8] Y. Kagawa,et al. Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. , 1989, Biochemical and biophysical research communications.
[9] C. Ward,et al. Parkinson's disease in 65 pairs of twins and in a set of quadruplets , 1983, Neurology.
[10] J. Parks,et al. Abnormalities of the electron transport chain in idiopathic parkinson's disease , 1989, Annals of neurology.
[11] J. Parks,et al. Spin trapping of azidyl and hydroxyl radicals in azide-inhibited rat brain submitochondrial particles. , 1994, Archives of biochemistry and biophysics.
[12] K. Jellinger,et al. Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's disease , 1994, Neuroscience Letters.
[13] W. Nicklas,et al. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. , 1985, Life sciences.
[14] David G. Nicholls,et al. Bioenergetics an Introduction to the Chemiosmotic Theory , 1982 .
[15] R. Mayeux,et al. Does a long preclinical period occur in Parkinson's disease? , 1991, Neurology.
[16] J. Bennett,et al. Reduction of MPP(+)-induced hydroxyl radical formation and nigrostriatal MPTP toxicity by inhibiting nitric oxide synthase. , 1994, Neuroreport.
[17] R. Benecke,et al. Electron transfer complexes I and IV of platelets are abnormal in Parkinson's disease but normal in Parkinson-plus syndromes. , 1993, Brain : a journal of neurology.
[18] D. A. Monte. Mitochondrial DNA and Parkinson's disease , 1991 .
[19] C. Marsden,et al. Mitochondrial function in Parkinson's disease , 1992, Annals of neurology.
[20] M. Runswick,et al. Complementary DNA sequences of two 14.5 kDa subunits of NADH:ubiquinone oxidoreductase from bovine heart mitochondria Completion of the primary structure of the complex? , 1992, FEBS letters.
[21] R. Ramsay,et al. Inhibition of mitochondrial NADH dehydrogenase by pyridine derivatives and its possible relation to experimental and idiopathic parkinsonism. , 1986, Biochemical and biophysical research communications.
[22] B. Djahanguiri,et al. The prevention of acute gastric ulcer in the rat by alpha-methyldopa. , 1967, Medicina et pharmacologia experimentalis. International journal of experimental medicine.
[23] K. Stuhlmeier,et al. A microplate assay for the detection of oxidative products using 2',7'-dichlorofluorescin-diacetate. , 1992, Journal of immunological methods.
[24] M. Ratinaud,et al. In situ flow cytometric analysis of nonyl acridine orange-stained mitochondria from splenocytes. , 1988, Cytometry.
[25] J. Kaprio,et al. Parkinson's disease in a nationwide twin cohort , 1988, Neurology.
[26] M. Yahr,et al. Impaired oxidative decarboxylation of pyruvate in fibroblasts from patients with Parkinson's disease , 1994, Journal of neural transmission. Parkinson's disease and dementia section.
[27] H. Reichmann,et al. Electron transport chain defects in Alzheimer's disease. , 1994, Neurology.
[28] O. Blin,et al. Mitochondrial respiratory failure in skeletal muscle from patients with Parkinson's disease and multiple system atrophy , 1994, Journal of the Neurological Sciences.
[29] D. Turnbull,et al. Respiratory chain abnormalities in skeletal muscle from patients with Parkinson's disease , 1991, Journal of the Neurological Sciences.
[30] S. Horai,et al. Is Parkinson's disease a mitochondrial disorder? , 1992, Journal of the Neurological Sciences.
[31] H. Misra,et al. Generation of reactive oxygen species during the monoamine oxidase-catalyzed oxidation of the neurotoxicant, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. , 1993, The Journal of biological chemistry.
[32] D. Johns. Seminars in medicine of the Beth Israel Hospital, Boston. Mitochondrial DNA and disease. , 1995, The New England journal of medicine.
[33] A Hofman,et al. Prevalence of Parkinson's disease in the elderly , 1995, Neurology.
[34] H. Weiss,et al. De novo synthesis and desaturation of fatty acids at the mitochondrial acyl‐carrier protein, a subunit of NADH:ubiquinone oxidoreductase in Neurospora crassa , 1992, FEBS letters.
[35] C. Marín,et al. Mitochondria1 respiratory chain activity in skeletal muscle from patients with Parkinson's disease , 1993, Neurology.
[36] M. Hoehn,et al. Parkinsonism , 1967, Neurology.
[37] Eugene M. Johnson,et al. Superoxide dismutase delays neuronal apoptosis: A role for reactive oxygen species in programmed neuronal death , 1995, Neuron.
[38] A. Torroni,et al. Mitochondrial oxidative phosphorylation defects in parkinson's disease , 1991, Annals of neurology.
[39] M. Beal,et al. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? , 1992, Annals of neurology.
[40] R. Morais,et al. Ethidium bromide-induced loss of mitochondrial DNA from primary chicken embryo fibroblasts , 1985, Molecular and cellular biology.
[41] C. Marsden. Parkinson's disease in twins. , 1987, Journal of neurology, neurosurgery, and psychiatry.
[42] L. Golbe. The genetics of Parkinson's disease: A reconsideration , 1990, Neurology.
[43] E. Shoubridge,et al. Deletion mutants are functionally dominant over wild-type mitochondrial genomes in skeletal muscle fiber segments in mitochondrial disease , 1990, Cell.
[44] T. Ozawa,et al. Point mutations of mitochondrial genome in Parkinson's disease. , 1995, Brain research. Molecular brain research.
[45] C. Marsden,et al. Mitochondrial Complex I Deficiency in Parkinson's Disease , 1990, Lancet.
[46] Robert Hill,et al. Low platelet mitochondrial complex I and complex II/III activity in early untreated parkinson's disease , 1995, Annals of neurology.
[47] J. Hayashi,et al. Introduction of disease-related mitochondrial DNA deletions into HeLa cells lacking mitochondrial DNA results in mitochondrial dysfunction. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[48] H. Yoshino,et al. Mitochondrial complex I and II activities of lymphocytes and platelets in Parkinson's disease , 1992, Journal of neural transmission. Parkinson's disease and dementia section.
[49] P. Desjardins,et al. An established avian fibroblast cell line without mitochondrial DNA , 1986, Somatic cell and molecular genetics.
[50] M. Beal,et al. Cortical Cytochrome Oxidase Activity Is Reduced in Alzheimer's Disease , 1994, Journal of neurochemistry.